| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
Year
Ended October 31, |
|
| |
|
2021 |
|
|
2020 |
|
| Net
income/(loss): |
|
|
|
|
|
|
|
|
| CAR-T
Therapeutics |
|
$ |
(5,672,622 |
) |
|
$ |
(2,241,443 |
) |
| Cancer
Vaccines |
|
|
(4,558,811 |
) |
|
|
(828,136 |
) |
| Anti-Viral
Therapeutics |
|
|
(2,927,979 |
) |
|
|
(1,168,969 |
) |
| Cancer
Diagnostics |
|
|
(78,067 |
) |
|
|
(5,836,594 |
) |
| Patent
Licensing |
|
|
109,556 |
|
|
|
(17,221 |
) |
| Total |
|
$ |
(13,127,923 |
) |
|
$ |
(10,092,363 |
) |
| |
|
|
|
|
|
|
|
|
| Total
operating costs and expenses |
|
$ |
13,648,192 |
|
|
$ |
9,978,202 |
|
| Less
non-cash share-based compensation |
|
|
(8,058,078 |
) |
|
|
(4,137,460 |
) |
Operating
costs and expenses excluding non-cash share-based compensation |
|
$ |
5,590,114 |
|
|
$ |
5,840,742 |
|
| |
|
|
|
|
|
|
|
|
Operating
costs and expenses excluding non-cash share based compensation: |
|
|
|
|
|
|
|
|
| CAR-T
Therapeutics |
|
$ |
2,421,487 |
|
|
$ |
1,141,542 |
|
| Cancer
Vaccines |
|
|
1,641,977 |
|
|
|
365,681 |
|
| Anti-Viral
Therapeutics |
|
|
1,080,279 |
|
|
|
739,140 |
|
| Cancer
Diagnostics |
|
|
49,170 |
|
|
|
3,581,377 |
|
| Patent
Licensing |
|
|
397,201 |
|
|
|
13,002 |
|
| Total |
|
$ |
5,590,114 |
|
|
$ |
5,840,742 |
|
| |
|
October
31, |
|
| |
|
2021 |
|
|
2020 |
|
| Total
assets: |
|
|
|
|
|
|
|
|
| CAR-T
Therapeutics |
|
$ |
15,067,933 |
|
|
$ |
2,988,124 |
|
| Cancer
Vaccines |
|
|
13,276,518 |
|
|
|
946,923 |
|
| Anti-Viral
Therapeutics |
|
|
7,368,214 |
|
|
|
2,464,361 |
|
| Cancer
Diagnostics |
|
|
391,618 |
|
|
|
2,869,529 |
|
| Patent
Licensing |
|
|
153,121 |
|
|
|
184,027 |
|
| Total |
|
$ |
36,257,404 |
|
|
$ |
9,452,964 |
|
|